Goldman Sachs ActiveBeta(R) World Low Vol Plus Equity ETF (GLOV)
- Previous Close
46.67 - Open
46.66 - Bid 46.66 x 800
- Ask 46.81 x 800
- Day's Range
46.60 - 46.69 - 52 Week Range
38.61 - 47.36 - Volume
52,579 - Avg. Volume
41,231 - Net Assets 881.35M
- NAV 46.75
- PE Ratio (TTM) 20.88
- Yield 1.91%
- YTD Daily Total Return 7.26%
- Beta (5Y Monthly) 0.00
- Expense Ratio (net) 0.25%
The fund seeks to achieve its investment objective by investing at least 80% of its assets in securities included in its underlying index, in depositary receipts representing securities included in its underlying index and in underlying stocks in respect of depositary receipts included in its underlying index. The index is designed to deliver exposure to large- and mid-capitalization equity securities of developed market issuers, including the United States.
Goldman Sachs
Fund Family
Global Large-Stock Blend
Fund Category
881.35M
Net Assets
2022-03-15
Inception Date
Performance Overview: GLOV
Trailing returns as of 6/7/2024. Category is Global Large-Stock Blend.
People Also Watch
Holdings: GLOV
Top 10 Holdings (14.59% of Total Assets)
Sector Weightings
Related ETF News
Research Reports: GLOV
Baxter Earnings: Legacy Hill Rom Woes Overshadow Rising Medical Utilization and 2024 Outlook
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment, including hospital beds, to the portfolio, although about half of Hillrom's revenue comes from more digitally connected offerings like its smart beds and Voalte medical communications app. From its legacy operations, Baxter offers tools to help patients with acute and chronic kidney failure, which it plans to spin off by mid-2024. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents.
RatingPrice TargetLowering target price to $164.00
NOVANTA INC has an Investment Rating of HOLD; a target price of $164.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetWhat does Argus have to say about NOVT?
NOVANTA INC has an Investment Rating of HOLD; a target price of $167.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetJohnson & Johnson Earnings: Solid Growth to Start the Year, but We Expect That to Slow by Midyear
Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. The consumer group is being divested in 2023 under the new name Kenvue. Geographically, just over half of total revenue is generated in the United States.
RatingPrice Target